Clinical trial
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or…
NCT00006458 · Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Other · Unknown status
Key facts
| NCT number | NCT00006458 |
|---|---|
| Title | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer |
| Official title | Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Radiation |
| Interventions | indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14 |
| Start date | Aug 1, 2000 |
| First posted | Apr 2, 2004 |
| Last update posted | Mar 3, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: